Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors
- 18 July 2015
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 19 (10) , 1339-1350
Abstract
(2015). Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors. Expert Opinion on Therapeutic Targets: Vol. 19, No. 10, pp. 1339-1350. doi: 10.1517/14728222.2015.1068759Keywords
This publication has 86 references indexed in Scilit:
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastomaActa Neuropathologica, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- Fifteen Years of Gene Therapy Based on Chimeric Antigen Receptors: “Are We Nearly There Yet?”Human Gene Therapy, 2009
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastomaNature Medicine, 2008
- HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significanceOncogene, 2008
- The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signalingOncogene, 2008
- Adoptive cell transfer: a clinical path to effective cancer immunotherapyNature Reviews Cancer, 2008
- Differential phosphorylation of NG2 proteoglycan by ERK and PKCα helps balance cell proliferation and migrationJournal of Cell Biology, 2007